(1999) Biochem. revealed that poly(ADP-ribose) polymerase-1 (PARP-1) bound to the ?0.4/?0.2-kb fragment that negatively regulated expression of in response to RANKL stimulation. Electrophoretic mobility shift assays with PARP-1-specific antibody located the binding site of PARP-1 to the TTCCCA consensus sequence. The expression of PARP-1 was reduced during RANKL-induced osteoclastogenesis, concurrently with increased expression of Ckb. Consistently, knockdown of PARP-1 by lentivirus-delivered shRNA enhanced mRNA expression. The activity of PARP-1 was determined to be required for its inhibitory effect on the expression. In summary, we have demonstrated that PARP-1 PF-06424439 methanesulfonate is a negative regulator of the expression. Down-regulation of PARP-1 is responsible for the up-regulation of during RANKL-induced osteoclastogenesis. (12). The mechanism may be related to decrease in regeneration of ATP, which is needed for cytoskeleton reorganization and bone resorption (12, 13). Therefore, understanding the modulation of the Ckb expression in osteoclasts may provide new insights into therapeutic strategy for osteolytic bone disorders. Transcriptional regulation of has been reported in rat and human cells (14,C20). Multiple binding sites for diverse nuclear transcription factors have been identified within the promoter. For instance, expression of was found to be regulated by transcriptional factors activator protein-2 and nuclear factor Y in U87-MG glioblastoma cells (16, 17). The sequences between ?75/?45 and ?568/?523 bp at human promoter have been characterized as estrogen-responsive regions, albeit the binding site for the estrogen receptor is only present in the ?568/?523-bp region (18,C20). In addition, other transcriptional factors, such as myocyte enhancer factor 2 and Sp1, have also been shown to initiate or sustain the transcription of (18, 21). Nevertheless, the regulation of in osteoclasts has yet to be determined. The receptor activator for nuclear factor B ligand (RANKL), a member of the tumor necrosis factor (TNF) superfamily, is a potent inducer of osteoclast differentiation, function, and survival. RANKL exerts its effects by binding to its receptor RANK, which interacts with various TNF receptor-associated factors to initiate intracellular signaling pathways, including nuclear factor B (NF-B), activator protein 1 (AP-1), and nuclear factor of activated T-cells (NFAT) c1 during RANKL-mediated osteoclastogenesis (22,C25). NFATc1 plays an PF-06424439 methanesulfonate integral role in the RANKL-induced transcriptional program during the late stage of differentiation. AP-1 transcription factors are important transcriptional partners of NFATc1 and are critical for the induction of NFATc1 (26). RANKL-induced NF-B, NFATc1, and AP-1 signaling pathways play essential roles in activating the expression of osteoclast-specific genes, such as tartrate-resistant acidic phosphatase (TRAP), cathepsin K (Cath K), and calcitonin receptor (CTR), thus promoting osteoclast differentiation and function. In the present studies, we investigated the molecular mechanisms of Ckb regulation during RANKL-induced osteoclastogenesis. We found that the poly(ADP-ribose) polymerase-1 (PARP-1) was a negative regulator of at the basal level and during RANKL-induced osteoclastogenesis. The effect of PARP-1 on the regulation of was characterized with a PARP-1-specific inhibitor and by PARP-1 knockdown. Furthermore, with the use of a luciferase reporter system and electrophoretic mobility shift assays, the PARP-1 binding domain was identified at 5 of the gene. These studies provide important insights into molecular regulation of Ckb and its function during RANKL-induced osteoclastogenesis. EXPERIMENTAL PROCEDURES Cell Cultures Primary mouse bone marrow macrophages (BMMs) were isolated from long bones of 6C8-week-old C57BL/6 mice, and osteoclast differentiation was induced by GST-RANKL (100 ng/ml) in the presence of macrophage colony-stimulating factor (M-CSF) as we described previously (27). The Raw 264.7 cells obtained from ATCC (Manassas, VA) were cultured in Dulbecco’s modified Eagle’s medium (Mediatech) containing 10% fetal bovine serum. Osteoclastogenesis was induced by 50 ng/ml RANKL and determined by TRAP staining according to the manufacturer’s instructions (Sigma). Knockdown of PARP-1 in BMMs with Lentivirus-delivered shRNA Four lentiviral constructs expressing a 21-nucleotide PARP-1 short hairpin RNA (shRNA) targeting murine PARP-1 gene (GenBankTM accession number “type”:”entrez-nucleotide”,”attrs”:”text”:”NM_007415″,”term_id”:”1343071472″,”term_text”:”NM_007415″NM_007415) were purchased from Open Biosystems (Huntsville, AL). Each PF-06424439 methanesulfonate construct was packed into lentivirus-like particles pseudotyped with the vesicular stomatitis virus glycoprotein as we previously described (28). Transduction was performed by incubating BMMs with recombinant lentivirus, and stably transduced cells were selected VEZF1 with puromycin (2 g/ml). Western Blot Analysis Western blot analysis was performed as we previously described (27). Goat polyclonal anti-Ckb, mouse monoclonal anti-NFATc1, and rabbit polyclonal anti-PARP-1 antibodies were purchased from Santa Cruz Biotechnology. Mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (RDI-TRK5G4-6C5) was obtained from Research Diagnostics Inc. Assessments of Gene Expression by RT-PCR and Quantitative Real-time PCR Total RNA was isolated from indicated cells with TRIzol reagents (Invitrogen), reverse-transcribed, and amplified with primers for mouse gene.